Pacer Advisors Inc. grew its position in Baxter International Inc (NYSE:BAX) by 20.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 58,089 shares of the medical instruments supplier’s stock after purchasing an additional 10,047 shares during the period. Pacer Advisors Inc.’s holdings in Baxter International were worth $5,081,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Weaver Consulting Group acquired a new position in shares of Baxter International in the first quarter valued at about $25,000. Personal Wealth Partners acquired a new position in shares of Baxter International in the second quarter valued at about $29,000. TRUE Private Wealth Advisors acquired a new position in shares of Baxter International in the second quarter valued at about $29,000. Old North State Trust LLC acquired a new position in shares of Baxter International in the third quarter valued at about $31,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Baxter International in the second quarter valued at about $32,000. 83.44% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on the company. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Wells Fargo & Co set a $95.00 target price on Baxter International and gave the stock a “buy” rating in a research note on Friday, July 26th. JPMorgan Chase & Co. set a $94.00 target price on Baxter International and gave the stock a “buy” rating in a research note on Tuesday. Barclays set a $82.00 target price on Baxter International and gave the stock a “hold” rating in a research note on Friday, July 26th. Finally, Royal Bank of Canada set a $87.00 target price on Baxter International and gave the stock a “hold” rating in a research note on Friday, July 26th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Baxter International presently has an average rating of “Buy” and an average target price of $85.67.
Shares of BAX opened at $88.03 on Friday. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $89.93. The company has a quick ratio of 2.10, a current ratio of 2.78 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $44.94 billion, a price-to-earnings ratio of 28.86, a PEG ratio of 2.01 and a beta of 0.99. The stock’s 50-day moving average price is $87.00 and its 200-day moving average price is $81.69.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.08. Baxter International had a return on equity of 21.21% and a net margin of 14.28%. The firm had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The company’s revenue was down .1% compared to the same quarter last year. As a group, equities analysts anticipate that Baxter International Inc will post 3.37 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 1st. Shareholders of record on Friday, August 30th were given a dividend of $0.22 per share. The ex-dividend date was Thursday, August 29th. This represents a $0.88 dividend on an annualized basis and a yield of 1.00%. Baxter International’s dividend payout ratio is currently 28.85%.
In other Baxter International news, Director James R. Gavin III sold 7,950 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $87.63, for a total transaction of $696,658.50. Following the transaction, the director now owns 40,932 shares in the company, valued at $3,586,871.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jacqueline Kunzler sold 5,934 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $88.12, for a total value of $522,904.08. Following the transaction, the senior vice president now owns 3,089 shares in the company, valued at approximately $272,202.68. The disclosure for this sale can be found here. Insiders have sold 14,064 shares of company stock worth $1,235,359 in the last quarter. 0.70% of the stock is currently owned by company insiders.
Baxter International Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Read More: Economic Bubble
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.